Single ascending dose study of IMM-01 in cancer patients

Trial Profile

Single ascending dose study of IMM-01 in cancer patients

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs IMM 01 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors TVM Life Science Ventures VII
  • Most Recent Events

    • 03 Feb 2016 New trial record
    • 01 Feb 2016 According to TVM Life Science media release, company is planning to file an Investigational New Drug (IND) application in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top